STOCK TITAN
  1. Home
  2. News
  3. IBRX

ImmunityBio, Inc. - IBRX STOCK NEWS

Welcome to our dedicated page for ImmunityBio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on ImmunityBio stock.

ImmunityBio, Inc. (symbol: IBRX) is a pioneering biotechnology company specializing in immuno-oncology and infectious disease treatments. With a focus on activating both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems, ImmunityBio is at the forefront of developing innovative molecular and product platforms.

The company's key platforms include the development of antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, as well as cell therapies. ImmunityBio is working on several significant product candidates, such as n-803, aldoxorubicin, and a second-generation adenovirus vector. These platforms are designed to activate natural killer (NK) cells, T cells, tumoricidal macrophages, and memory T cells, providing a comprehensive approach to cancer treatment and infectious disease management.

Anktiva, one of ImmunityBio's leading product candidates, is an IL-15 superagonist antibody-cytokine fusion protein, which enhances the body's immune response against cancer cells. The company's pipeline includes treatments targeting bladder, lung, and colorectal cancers, as well as glioblastoma multiforme (GBM).

Headquartered in the United States, ImmunityBio operates across two geographical segments: the United States and Europe, with key revenue generated from European markets. The company is integrated from discovery and development to commercialization, ensuring a seamless transition of its products from the laboratory to the market.

ImmunityBio has achieved several milestones, including the initiation of pivotal clinical trials and strategic partnerships with leading research institutions. These accomplishments underscore the company's commitment to transforming the landscape of immuno-oncology and infectious disease treatment.

Stay informed about ImmunityBio's latest developments, financial performance, and upcoming projects by visiting our news section regularly.

News

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

Rhea-AI Summary

ImmunityBio's Executive Chairman, Dr. Patrick Soon-Shiong, will discuss the recent FDA approval of ANKTIVA® for use in combination with BCG for non-muscle invasive bladder cancer at the AUA 2024 conference. ANKTIVA's Breakthrough Therapy designation and novel mechanism will be highlighted, offering an alternative therapy to radical surgery for advanced bladder cancer cases. The discussion will focus on transforming cold bladder cancer cells to hot tumors via ANKTIVA's activation of NK and T cells, resulting in durable responses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.12%
Tags
none
-
News

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

Rhea-AI Summary
ImmunityBio, Inc. (NASDAQ: IBRX) announces positive overall survival results in the QUILT 3.055 trial for non-small cell lung cancer patients who did not respond to checkpoint inhibitors. The study showed a nearly double median overall survival compared to standard chemotherapy. ANKTIVA, an immune cell enhancer, displayed efficacy in PD-L1 negative and positive patients, activating natural killer cells and memory T cells. A meeting with the FDA is scheduled to discuss registration for ANKTIVA in combination with checkpoint inhibitors. The company received a $100 million non-dilutive cash infusion, bringing cash-on-hand to $240 million for the launch of ANKTIVA in bladder cancer. ImmunityBio plans to discuss registration plans and clinical trial pipeline during a conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.02%
Tags
none
-
News

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Rhea-AI Summary
ImmunityBio's ANKTIVA, a first-in-class IL-15 receptor agonist, receives FDA approval as a breakthrough therapy for BCG-unresponsive non-muscle invasive bladder cancer. The therapy activates the body's immune system to target tumor cells, leading to long-lasting complete responses. ANKTIVA in combination with BCG shows durable responses exceeding 47 months, exceeding clinical benchmarks. Availability in the U.S. is expected by mid-May 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.13%
Tags
fda approval
News

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

Rhea-AI Summary
ImmunityBio (IBRX) announces promising preclinical data on N-803 and broadly neutralizing antibodies for HIV treatment. Clinical trials underway to test viral load reduction in HIV-infected individuals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
none
-
News

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

Rhea-AI Summary
ImmunityBio (NASDAQ: IBRX) announces positive results from a Phase 1 pilot study showing N-803 combined with natural killer cells may reduce viral load in HIV patients. All participants experienced a significant decrease in infection levels. The approach was safe and well-tolerated, paving the way for further research in HIV cure-related clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
none
-
News

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Rhea-AI Summary
ImmunityBio (IBRX) announces enrollment in a national trial testing Nant Cancer Vaccine for Lynch syndrome individuals to prevent colon and other cancers. The study includes a tri-valent Adenovirus and IL-15 superagonist N-803 to activate immune cells. Lynch syndrome patients are at high risk for various cancers. The trial aims to prevent cancer by targeting cancer-specific proteins and enhancing immune response. Enrollment for the safety portions of the trial is completed, with a total of 186 participants expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
News

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

Rhea-AI Summary
ImmunityBio, Inc. (IBRX) announces positive Patient-Reported Outcomes (PROs) from the QUILT 3.032 trial of N-803 plus BCG for non-muscle invasive bladder cancer. The PROs indicate stability of physical function and global health in patients who completed questionnaires and reached month 24 on-study, supporting the safety and tolerability of the potential new treatment combination. The FDA is reviewing the Biologics License Application (BLA) for N-803 plus BCG, with a PDUFA date of April 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
News

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

Rhea-AI Summary
ImmunityBio, Inc. (NASDAQ: IBRX) announced a $320 million royalty financing and equity investment by Oberland Capital, providing financial resources for commercialization efforts and pipeline expansion. The investment is non-dilutive and includes $200 million funded at closing, with the potential for an additional $100 million contingent upon FDA approval of Anktiva® for the treatment of bladder cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
none
-
News

ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary
ImmunityBio, Inc. (NASDAQ: IBRX) to participate in the 35th Annual Piper Sandler Healthcare Conference in New York City on November 28-30, 2023. The presentation will be a fireside chat with Director and Senior Research Analyst Joseph Catanzaro, Ph.D. The webcast link for the event will be available for replay on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity

Rhea-AI Summary
ImmunityBio, Inc. (NASDAQ: IBRX) announced promising findings from a study on Memory Cytokine-Enriched Natural Killer cells (M-ceNK) suggesting potential benefits for patients with small cell lung cancer and other neuroendocrine tumors. The study presented at the Society for Immunotherapy of Cancer annual meeting revealed M-ceNK cells' effectiveness in targeting SCLC and other neuroendocrine cancers, indicating a new immunotherapy approach for unresponsive cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none

FAQ

What is the current stock price of ImmunityBio (IBRX)?

The current stock price of ImmunityBio (IBRX) is $5.28 as of November 1, 2024.

What is the market cap of ImmunityBio (IBRX)?

The market cap of ImmunityBio (IBRX) is approximately 3.7B.

What does ImmunityBio, Inc. specialize in?

ImmunityBio specializes in immuno-oncology and infectious disease treatments, focusing on activating both the innate and adaptive immune systems.

What are the key product candidates of ImmunityBio?

Key product candidates include n-803, aldoxorubicin, and Anktiva, an IL-15 superagonist antibody-cytokine fusion protein.

Which cancers does ImmunityBio focus on treating?

ImmunityBio focuses on treating bladder, lung, and colorectal cancers, as well as glioblastoma multiforme (GBM).

What geographical segments does ImmunityBio operate in?

ImmunityBio operates in two geographical segments: the United States and Europe, with key revenue generated from Europe.

What types of therapies is ImmunityBio developing?

ImmunityBio is developing antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, as well as cell therapies.

How does ImmunityBio's Anktiva work?

Anktiva is an IL-15 superagonist antibody-cytokine fusion protein that enhances the body's immune response against cancer cells.

What recent achievements has ImmunityBio made?

ImmunityBio has initiated pivotal clinical trials and formed strategic partnerships with leading research institutions.

Where can I find the latest news about ImmunityBio?

You can stay informed about ImmunityBio's latest developments by visiting the news section on our website.

What is ImmunityBio's business model?

ImmunityBio is an integrated biotechnology company involved in discovering, developing, and commercializing immuno- and cellular therapies.

How does ImmunityBio contribute to cancer treatment?

ImmunityBio develops therapies that activate NK cells, T cells, tumoricidal macrophages, and memory T cells to enhance the immune system's ability to fight cancer.

Stock IBRX logo
ImmunityBio, Inc.

Nasdaq:IBRX

IBRX Rankings

#1473 Ranked by Market Cap
N/A Ranked by Dividends

IBRX Stock Data

3.68B
696.53M
77.04%
9.13%
7.41%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO